Chemomab Therapeutics Ltd. Sponsored ADR CMMB
2.16
(0.04)
(1.82%)
as of 25 Sep
- Market cap
- $16.0M
- P/E
- 0.0×
Follow CMMB
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(73.21%) | (69.54%) | (70.61%) | (82.17%) | |
| (60.63%) | (58.45%) | (60.46%) | (70.70%) | ||
ROIC |
(658.26%) | (303.83%) | (186.89%) | (247.40%) | |
Return on Tangible Assets |
(91.87%) | (74.20%) | (70.72%) | (88.22%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (6.25) | 0.00 | (4.55) | |
Free Cash Flow |
— | (39.86) | — | (36.41) | |
Capital Expenditures |
— | 0.00 | — | (0.01) | |
| Other line items | |||||
Cash ROIC |
0.00% | (175.56%) | 0.00% | (236.82%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 4.43 | 0.00 | 4.82 | |
Depreciation/Fixed assets |
0.00 | 1.04 | 0.00 | 1.12 | |
Capex/Depreciation |
— | (0.03) | — | (0.03) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | (6.25) | 0.00 | (4.55) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates